Shō Boku

Recent publications · Crossref

5 total works indexed

1. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

   · 2017 · cited 1,923x

2. Signaling from Rho to the Actin Cytoskeleton Through Protein Kinases ROCK and LIM-kinase

   · 1999 · cited 1,333x

3. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

   · 2016 · cited 980x

4. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

   · 2022 · cited 704x

5. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

   · 2017 · cited 642x

via Crossref · CC0